177 related articles for article (PubMed ID: 22960341)
41. Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients.
Di Carlo A; Mariano A; Terracciano D; Ferro M; Montanaro V; Marsicano M; Di Lorenzo G; Altieri V; Macchia V
Oncol Rep; 2010 Jul; 24(1):3-8. PubMed ID: 20514437
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder.
Candido S; Di Maso M; Serraino D; McCubrey JA; Bortolus R; Zanin M; Battiston M; Salemi R; Libra M; Polesel J
Tumour Biol; 2016 Jul; 37(7):9855-63. PubMed ID: 26810191
[TBL] [Abstract][Full Text] [Related]
43. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker.
Melissourgos N; Kastrinakis NG; Davilas I; Foukas P; Farmakis A; Lykourinas M
Urology; 2003 Aug; 62(2):362-7. PubMed ID: 12893365
[TBL] [Abstract][Full Text] [Related]
44. The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.
Smrkolj T; Cegovnik Primozic U; Fabjan T; Sterpin S; Osredkar J
Radiol Oncol; 2020 Dec; 55(2):196-202. PubMed ID: 33764701
[TBL] [Abstract][Full Text] [Related]
45. THE SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND SURVIVIN EXPRESSION IN BLADDER CANCER TISSUE AND URINE CYTOLOGY OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER.
Kehinde EO; Al-Maghrebi M; Anim JT; Kapila K; George SS; Al-Juwaiser A; Memon A
East Afr Med J; 2013 Jan; 90(1):19-27. PubMed ID: 26862626
[TBL] [Abstract][Full Text] [Related]
46. Performance of urinary survivin as a non-invasive molecular marker of bladdercarcinoma in a schistosomiasis endemic area.
Muhammad AS; Mungadi IA; Ndodu ED; Kalayi GD
Ghana Med J; 2018 Jun; 52(2):74-78. PubMed ID: 30662078
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of urinary human telomerase reverse transcriptase mRNA and scatter factor protein as urine markers for diagnosis of bladder cancer.
Eissa S; Motawi T; Badr S; Zaghlool A; Maher A
Clin Lab; 2013; 59(3-4):317-23. PubMed ID: 23724620
[TBL] [Abstract][Full Text] [Related]
48. Multiplex protein signature for the detection of bladder cancer in voided urine samples.
Rosser CJ; Ross S; Chang M; Dai Y; Mengual L; Zhang G; Kim J; Urquidi V; Alcaraz A; Goodison S
J Urol; 2013 Dec; 190(6):2257-62. PubMed ID: 23764080
[TBL] [Abstract][Full Text] [Related]
49. Detection of urine survivin in 40 patients with bladder cancer.
Ohsawa I; Nishimura T; Kondo Y; Kimura G; Satoh M; Matsuzawa I; Hamasaki T; Ohta S
J Nippon Med Sch; 2004 Dec; 71(6):379-83. PubMed ID: 15673958
[TBL] [Abstract][Full Text] [Related]
50. A novel approach to using matrix metalloproteinases for bladder cancer.
Fernández CA; Wszolek MF; Loughlin KR; Libertino JA; Summerhayes IC; Shuber AP
J Urol; 2009 Nov; 182(5):2188-94. PubMed ID: 19758628
[TBL] [Abstract][Full Text] [Related]
51. Editorial comment on: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Babjuk M
Eur Urol; 2007 Nov; 52(5):1396-7. PubMed ID: 17466449
[No Abstract] [Full Text] [Related]
52. Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine.
Nutt JE; Durkan GC; Mellon JK; Lunec J
BJU Int; 2003 Jan; 91(1):99-104. PubMed ID: 12614260
[TBL] [Abstract][Full Text] [Related]
53. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
54. The expression and significance of survivin mRNA in urinary bladder carcinomas.
Wang H; Xi X; Kong X; Huang G; Ge G
J Cancer Res Clin Oncol; 2004 Aug; 130(8):487-90. PubMed ID: 15138808
[TBL] [Abstract][Full Text] [Related]
55. Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen.
Johnen G; Gawrych K; Bontrup H; Pesch B; Taeger D; Banek S; Kluckert M; Wellhäußer H; Eberle F; Nasterlack M; Leng G; Stenzl A; Brüning T;
PLoS One; 2012; 7(4):e35363. PubMed ID: 22530010
[TBL] [Abstract][Full Text] [Related]
56. Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
Balci M; Tuncel A; Guzel O; Aslan Y; Sezgin T; Bilgin O; Senel C; Atan A
Int Urol Nephrol; 2015 Mar; 47(3):473-7. PubMed ID: 25649031
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
58. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology.
Eissa S; Salem AM; Zohny SF; Hegazy MG
Cancer Biomark; 2007; 3(6):275-85. PubMed ID: 18048965
[TBL] [Abstract][Full Text] [Related]
59. Evaluation and screening of mRNA S100A genes as serological biomarkers in different stages of bladder cancer in Egypt.
Ismail MF; El Boghdady NA; Shabayek MI; Awida HA; Abozeed H
Tumour Biol; 2016 Apr; 37(4):4621-31. PubMed ID: 26508026
[TBL] [Abstract][Full Text] [Related]
60. [Value of fluorescence in situ hybridization of urine exfoliative cells in diagnosis of urinary bladder neoplasms].
Chen N; Gong J; Zeng H; Wei Q; Zhu YC; Chen M; Zhou Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):109-13. PubMed ID: 21355314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
